University of Hertfordshire

Dr Yuen Ki Cheong

Yuen Ki Cheong

Dr Yuen Ki Cheong

Postal address:
University of Hertfordshire, Hatfield, Hertfordshire
United Kingdom

Overview

Dr Yuen-Ki Cheong is a RSC Chartered Chemist, who is also a member of the Women Engineering Society. She graduated with MSci in Pharmaceutical Chemistry and her PhD in Chemistry was gained in 2008 at Queen Mary University of London. She has over 8 years of research experience in multi-disciplinary projects involving applied and synthetic chemistry of bio-materials.

Yuen-Ki’s current research interest is focused in the development of Antimicrobial nanoparticle filters for water and air systems (EPSRC EP/N034368/1 £219K). This project involves creations of super antimicrobial formulations using Nanomaterials, which are made suitable for the incorporations into polymeric fibres for the pressurised gyration process. Antiviral formulations developed from previous project using TesimaTM thermal plasma technology (US patent 2013/0091611 A1) showed engineered nanomaterials exhibited generic inhibitory effects against a wide spectrum of deadly viruses and bacteria.  In order to validate the quality of these applied antimicrobial nanomaterials and to understand the interactions between these nanoparticles with harmful microorganisms, the physical, elemental and structural properties of each effective nanomaterials are fully characterised using different techniques, such as SEM, ICP-OES, Nanoparticles tracking analysis, etc. Along with the qualitative and quantitative analyses, the team has also established facilities in the School of Life Sciences to extend the scope of research to perform routine antimicrobial testing using nanomaterials that are being investigated.

As part of the larger project, Yuen-Ki is also researching a novel class of medically related compound called ‘Trisphosphonate’, where their chemical structures and syntheses were first published in 2014 (Taylor & Francis Online). These newly developed compounds fall in to the same category of a type of drug called the ‘Bisphosphonate’, which is known as the first-line treatments for many bone diseases, skeletal complications involving excessive bone resorption and hypercalcimia associated with bone malignancy. Following papers published in Neurochemical Research (2015) and General Medicine Open (2017) had demonstrated that Trisphosphonates have great potential in both neuro- and osteo- protections.

View graph of relations

View all (22) »

ID: 10382993